These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25180131)

  • 41. Anti-Hyperuricemic Effect of Iron Oxide Nanoparticles against Monosodium Urate Crystals Induced Gouty Arthritis in BALB/c Mice.
    Kiyani MM; Moghul NB; Butt MA; Rehman H; Masood R; Rajput TA; Bokhari SAI
    Biol Trace Elem Res; 2022 Apr; 200(4):1659-1666. PubMed ID: 34196880
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-hyperuricemic and nephroprotective effects of Modified Simiao Decoction in hyperuricemic mice.
    Hua J; Huang P; Zhu CM; Yuan X; Yu CH
    J Ethnopharmacol; 2012 Jun; 142(1):248-52. PubMed ID: 22575704
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnosis and treatment of gouty arthritis.
    TALBOTT JH
    Calif Med; 1953 Sep; 79(3):220-6. PubMed ID: 13082423
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Asymptomatic Hyperuricemia: Treatment Approaches According to the Risk of Cardiovascular and Renal Events].
    Kobalava ZD; Troitskaya EA
    Kardiologiia; 2021 Jan; 60(12):104-109. PubMed ID: 33522474
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease.
    Fujimori S; Ooyama K; Ooyama H; Moromizato H
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1035-8. PubMed ID: 22132953
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout.
    Perez-Ruiz F; Hernandez-Baldizon S; Herrero-Beites AM; Gonzalez-Gay MA
    Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1299-305. PubMed ID: 20506124
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Control of flares and relief of urate burden with canakinumab and targeted urate-lowering therapy in tophaceous gouty arthritis.
    Fanouriakis A; Karantanas A; Fragouli E; Repa A; Sidiropoulos P
    Rheumatology (Oxford); 2014 Apr; 53(4):764-6. PubMed ID: 24185764
    [No Abstract]   [Full Text] [Related]  

  • 48. Stopping progression in familial juvenile hyperuricemic nephropathy with benzbromarone?
    Lhotta K
    Kidney Int; 2003 Nov; 64(5):1920-1. PubMed ID: 14531831
    [No Abstract]   [Full Text] [Related]  

  • 49. [Serum uric acid--a cardiovasular risk factor?].
    Alderman M; Redfern JS
    Ther Umsch; 2004 Sep; 61(9):547-52. PubMed ID: 15493113
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of Rebixiao granules on blood uric acid in patients with repeatedly attacking acute gouty arthritis.
    Ji W; Zhu XX; Tan WF; Lu Y
    Chin J Integr Med; 2005 Mar; 11(1):15-21. PubMed ID: 15975301
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of low dose daily aspirin on serum urate levels and urinary excretion in patients receiving probenecid for gouty arthritis.
    Harris M; Bryant LR; Danaher P; Alloway J
    J Rheumatol; 2000 Dec; 27(12):2873-6. PubMed ID: 11128679
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Febuxostat: drug review and update.
    Grewal HK; Martinez JR; Espinoza LR
    Expert Opin Drug Metab Toxicol; 2014 May; 10(5):747-58. PubMed ID: 24684266
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Total saponins from Discorea nipponica ameliorate urate excretion in hyperuricemic mice.
    Zhou Q; Yu DH; Zhang C; Liu SM; Lu F
    Planta Med; 2014 Oct; 80(15):1259-68. PubMed ID: 25248048
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute gouty arthritis. Modern approaches to an ancient disease.
    Tan N; Lertratanakul Y; Barr WG
    Postgrad Med; 1993 Aug; 94(2):73-5, 78, 83-4 passim. PubMed ID: 8341627
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Hyperuricemia and gout].
    Gröbner W
    Dtsch Med Wochenschr; 2015 Oct; 140(21):1615-26. PubMed ID: 26488103
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Metabolic disorder of purine nucleotide in patients with renal disease].
    Hosoya T; Ohno I; Ichida K; Sakai O
    Nihon Rinsho; 1996 Dec; 54(12):3354-9. PubMed ID: 8976119
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts.
    Perez-Ruiz F; Calabozo M; Herrero-Beites AM; García-Erauskin G; Pijoan JI
    Nephron; 2000 Nov; 86(3):287-91. PubMed ID: 11096285
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Autosomal dominant transmission of gouty arthritis with renal disease in a large Japanese family.
    Yokota N; Yamanaka H; Yamamoto Y; Fujimoto S; Eto T; Tanaka K
    Ann Rheum Dis; 1991 Feb; 50(2):108-11. PubMed ID: 1847794
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of asymptomatic hyperuricemia.
    Duffy WB; Senekjian HO; Knight TF; Weinman EJ
    JAMA; 1981 Nov; 246(19):2215-6. PubMed ID: 7289015
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.